US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020
Nadine Shehab, Maribeth C. Lovegrove, Daniel S. Budnitz
Abstract
The voices of women in cardiovascular clinical research are not being heard, and the losses are tangible. Women lose rewarding careers, trainees lose valuable role models, patients lose inclusiveness in clinical trials, and research loses crucial perspectives. Career advancement benefits associated with clinical trial leadership extend well beyond manuscript authorship; these include research funding support, presentations at prestigious and highly visible late-breaking clinical trial sessions at the large annual scientific sessions, institutional and media recognition, and thought leadership reputation that leads to future, higher-effect opportunities. Advances in women's leadership in academic medicine have historically preceded advances in women's health, and there remains room for improvement on both. 5 Disease manifestation, risk factors, and treatments of cardiovascular conditions in women remain understudied. Enrollment of women in clinical trials of heart failure and acute coronary syndrome still lag behind disease prevalence in the general population, which likely reflects the paucity of female leadership in these trials. 6 In contrast, the Women's Health Initiative, with strong female study leadership, successfully enrolled almost a half million women.